RT Journal Article
SR Electronic
T1 Vaccine effectiveness for preventing COVID-19 hospital admission during pregnancy: a population-based cohort study in England during the Alpha and Delta waves of the SARS-CoV-2 pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.27.22280397
DO 10.1101/2022.09.27.22280397
A1 Bosworth, Matthew L.
A1 Schofield, Ryan
A1 Ayoubkhani, Daniel
A1 Charlton, Loes
A1 Nafilyan, Vahé
A1 Khunti, Kamlesh
A1 Zaccardi, Francesco
A1 Gillies, Clare
A1 Akbari, Ashley
A1 Knight, Marian
A1 Wood, Rachael
A1 Hardelid, Pia
A1 Zuccolo, Luisa
A1 Harrison, Camille
YR 2022
UL http://medrxiv.org/content/early/2022/09/27/2022.09.27.22280397.abstract
AB Objective To estimate vaccine effectiveness (VE) for preventing COVID-19 hospital admission in women first infected with SARS-CoV-2 during pregnancy, and assess how this compares to VE among women of reproductive age who were not pregnant when first infected.Design Population-based cohort study using national, linked Census and administrative data.Setting England, United Kingdom, from 8th December 2020 to 31st August 2021.Participants 815,4777 women aged 18 to 45 years (mean age, 30.4 years) who had documented evidence of a first SARS-CoV-2 infection in NHS Test and Trace data or Hospital Episode Statistics.Main outcome measures A hospital inpatient episode where COVID-19 was recorded as the primary diagnosis. Cox proportional hazards models, adjusted for calendar time of infection and sociodemographic factors related to vaccine uptake and risk of severe COVID-19, were used to estimate VE as the complement of the hazard ratio for COVID-19 hospital admission.Results Compared with unvaccinated pregnant women, the adjusted rate of COVID-19 hospital admission was 76% (95% confidence interval 69% to 82%) lower for single-vaccinated pregnant women and 83% (75% to 88%) lower for double-vaccinated pregnant women. These estimates were similar to those found for non-pregnant women: 79% (76% to 81%) for single-vaccinated and 82% (80% to 83%) for double-vaccinated. Among those vaccinated more than 90 days before infection, being double-vaccinated was associated with a greater reduction in risk than being single-vaccinated.Conclusions COVID-19 vaccination is associated with reduced rates of severe illness in pregnant women infected with SARS-CoV-2, and the reduction in risk is similar to that for non-pregnant women. Waning of vaccine effectiveness occurs more quickly after one dose of a vaccine than two doses.What is already known on this topic Being pregnant is a risk factor for severe illness and mortality following infection with SARS-CoV-2.Existing evidence suggests that COVID-19 vaccines are effective for preventing severe outcomes in pregnant women.However, research directly comparing vaccine effectiveness between pregnant and non-pregnant women of reproductive age at the population level are lacking.What this study adds Our study provides real-world evidence that COVID-19 vaccination reduces the risk of hospital admission by a similar amount for both women infected with SARS-CoV-2 during pregnancy and women who were not pregnant when infected, during the Alpha and Delta dominant periods in England.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; MK is chair of the DMC for the Preg-CoV study. KK is a member of the UK Scientific Advisory Group for Emergencies (SAGE) and chair of the ethnicity subgroup of SAGE. PH has participated in a meeting of the Pfizer Respiratory Syncytial Virus Vaccine Advisory Board. Participation was unpaid.Funding StatementThis study received no specific funding. AA is part of, and supported by, the Con-COV team funded by the Medical Research Council (grant ref: MR/V028367/1), and also supported by Health Data Research UK (grant ref: HDR-9006) and ADR Wales (grant ref: ES/S007393/1). DA is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM). LZ received support from the Data and Connectivity National Core Study funding scheme, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058), and also supported by The Alan Turing Institute via 'Towards Turing 2.0' EPSRC Grant Funding. MK is an NIHR Senior Investigator. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. PH is based at the UCL Great Ormond Street Institute of Child Health; the Institute is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre (grant reference number: IS-BRC-1215-20012). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the National Statistician's Data Ethics Advisory Committee (NSDEC(20)12).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIn accordance with NHS Digital's Information Governance requirements, the study data cannot be shared.